Genmab to buy back 370,000 shares

The biotech firm has initiated a share buy-back program to mitigate dilution from warrants.
Jan van de Winkel, CEO of Genmab | Photo: PR / Genmab
Jan van de Winkel, CEO of Genmab | Photo: PR / Genmab
by marketwire, translated by daniel pedersen

A total of 370,000 Genmab shares will be repurchased by the biotech firm itself, according to a company press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading